Sarepta Therapeutics (NASDAQ:SRPT) Given New $35.00 Price Target at Jefferies Financial Group

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its price objective reduced by equities researchers at Jefferies Financial Group from $40.00 to $35.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the biotechnology company's stock. Jefferies Financial Group's price objective indicates a potential upside of 224.52% from the stock's previous close.

Several other equities analysts have also commented on the company. Oppenheimer lowered their target price on Sarepta Therapeutics from $45.00 to $41.00 and set an "outperform" rating for the company in a report on Friday, July 18th. BMO Capital Markets reaffirmed a "market perform" rating and set a $50.00 target price (down from $70.00) on shares of Sarepta Therapeutics in a report on Monday. Morgan Stanley reissued an "equal weight" rating and issued a $40.00 price objective (down from $113.00) on shares of Sarepta Therapeutics in a report on Monday, June 16th. TD Cowen lowered Sarepta Therapeutics from a "buy" rating to a "hold" rating and set a $24.00 price objective for the company. in a report on Wednesday, June 18th. Finally, William Blair reissued a "market perform" rating on shares of Sarepta Therapeutics in a report on Thursday, July 17th. Three research analysts have rated the stock with a sell rating, eighteen have given a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $51.42.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock traded down $2.54 during mid-day trading on Thursday, hitting $10.79. 17,030,019 shares of the company were exchanged, compared to its average volume of 4,585,906. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The business's 50 day simple moving average is $27.51 and its two-hundred day simple moving average is $66.42. The company has a market capitalization of $1.06 billion, a P/E ratio of -4.01 and a beta of 0.45. Sarepta Therapeutics has a 12-month low of $10.47 and a 12-month high of $150.48.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The company had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. During the same quarter in the prior year, the firm earned $0.73 EPS. The company's revenue for the quarter was up 80.2% compared to the same quarter last year. Analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. EP Wealth Advisors LLC lifted its stake in Sarepta Therapeutics by 2.2% in the fourth quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock valued at $606,000 after buying an additional 105 shares during the last quarter. Virtus ETF Advisers LLC raised its stake in shares of Sarepta Therapeutics by 6.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,809 shares of the biotechnology company's stock worth $342,000 after purchasing an additional 174 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in Sarepta Therapeutics by 4.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,699 shares of the biotechnology company's stock worth $571,000 after acquiring an additional 218 shares during the period. NEOS Investment Management LLC grew its holdings in Sarepta Therapeutics by 13.9% during the fourth quarter. NEOS Investment Management LLC now owns 1,943 shares of the biotechnology company's stock worth $236,000 after acquiring an additional 237 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Sarepta Therapeutics by 11.1% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,429 shares of the biotechnology company's stock worth $307,000 after acquiring an additional 243 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.